, conducted evaluations with the highest and lowest rates of positive reimbursement decisions: 100% (n = 29) and 57% (n = 30), respectively. No significant association was found between ERG group and reimbursement decision (p = 0.0930). Review year, oncology status, and review type were all tested as possible confounders. Of the models tested, the only significant relationship found was between review type and reimbursement decision, with indications reviewed through the MTA process being 60% less likely to receive reimbursement than those reviewed through the STA process (HSTs omitted from the model because of over-fitting). While reviews evaluated by different ERG groups had different rates of reimbursement, the difference was not statistically significant. The relationship between review type and reimbursement decision should be explored in future research.